Lorand Laboratories LLC (Lorand Labs) released a statement regarding a landmark study published last month in the Journal of Alzheimer’s Disease in which one of its Aloe vera products BiAloe® was used. The one-year-long University of Miami study measured the effects of an Aloe polymannose multinutrient complex on cognitive and immune functioning in advanced Alzheimer’s disease patients. The study suggests potential cognitive benefits of the daily consumption of an Aloe polymannose (a.k.a. Acemannan) multinutrient complex.
While Lorand Labs’ management was extremely encouraged by the results of the study, they were quick to caution that much more research needs to be conducted to determine if any benefit can be derived from the long term use of an Aloe polymannose multinutrient complex that uses BiAloe as the Acemannan component.
“We do not want our industry audiences or the public to think that Lorand Labs believes that BiAloe is in any way a treatment, cure or prevention of any disease. We know and believe that the results of this pilot study are very interesting and show promise; however, more independent research needs to be done to determine if any long‐term benefit can be derived from the daily use of a BiAloe multinutrient complex.” said Dr. Santiago Rodriguez, CEO of Lorand Labs.